{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:40:28Z","timestamp":1792820428969,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.11.042","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T04:02:49Z","timestamp":1607572969000},"page":"202-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials"],"prefix":"10.1016","volume":"39","author":[{"given":"Nicholas","family":"Dulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Spanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack N","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige E","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2020.11.042_b0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00705-012-1454-0","article-title":"Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae","volume":"158","author":"Kuhn","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2020.11.042_b0010","unstructured":"WHO. Marburg Virus Disease. 2012 2012 November; Fact sheet]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs_marburg\/en\/."},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.042_b0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11262-017-1455-x","article-title":"Ebola and Marburg virus vaccines","volume":"53","author":"Reynolds","year":"2017","journal-title":"Virus Genes"},{"key":"10.1016\/j.vaccine.2020.11.042_b0020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04395","article-title":"Mapping the zoonotic niche of Ebola virus disease in Africa","volume":"3","author":"Pigott","year":"2014","journal-title":"eLife."},{"issue":"6","key":"10.1016\/j.vaccine.2020.11.042_b0025","doi-asserted-by":"crossref","first-page":"366\u00b178","DOI":"10.1093\/trstmh\/trv024","article-title":"Mapping the zoonotic niche of Marburg virus disease in Africa","volume":"109","author":"Pigott","year":"2015","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"2","key":"10.1016\/j.vaccine.2020.11.042_b0030","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.06.020703","article-title":"Ebola research funding: a systematic analysis, 1997\u20132015","volume":"6","author":"Fitchett","year":"2016","journal-title":"J Glob Health."},{"issue":"2018","key":"10.1016\/j.vaccine.2020.11.042_b0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","article-title":"The WHO R&D Blueprint: 2018 review of emerging infections diseases requiring urgent research and development efforts","volume":"159","author":"Si Mehand","year":"2018","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.vaccine.2020.11.042_b0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJMoa051465","article-title":"Marburg hemorrhagic fever associated with multiple genetic lineages of virus","volume":"355","author":"Bausch","year":"2006","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1016\/j.vaccine.2020.11.042_b0045","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.00069-06","article-title":"Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola","volume":"80","author":"Towner","year":"2006","journal-title":"J Virol."},{"issue":"9","key":"10.1016\/j.vaccine.2020.11.042_b0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.medmal.2014.08.005","article-title":"Case fatality rates of Ebola virus diseases: a meta-analysis of World Health Organization data","volume":"44","author":"Lefebvre","year":"2014","journal-title":"Med Mal Infect."},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2020.11.042_b0055","doi-asserted-by":"crossref","first-page":"S796","DOI":"10.1093\/infdis\/jir312","article-title":"Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007","volume":"204","author":"Adjemian","year":"2011","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.042_b0060","unstructured":"Uganda ends Marburg virus disease outbreak. Available at: http:\/\/www.who.int\/en\/news-room\/detail\/08-12-2017-uganda-ends-marburg-virus-disease-outbreak. Accessed May 8, 2018."},{"key":"10.1016\/j.vaccine.2020.11.042_b0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Method"},{"issue":"9977","key":"10.1016\/j.vaccine.2020.11.042_b0070","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomized, double-blind, placebo-controlled clinical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.11.042_b0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a Phase I clinical trial","volume":"211","author":"Sarwar","year":"2015","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2020.11.042_b0080","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus Type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"S5","key":"10.1016\/j.vaccine.2020.11.042_b0085","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","article-title":"Postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of marburg virus variant angola in nonhuman primates","volume":"218","author":"Woolsey","year":"2018","journal-title":"J Inf Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.042_b0090","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure treatment of Marburg virus infection","volume":"16","author":"Geisbert","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.042_b0095","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg Haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment","volume":"367","author":"Daddario-DiCaprio","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2020.11.042_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2020.11.042_b0105","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.042_b0110","doi-asserted-by":"crossref","unstructured":"Geisbert TW, Geisbert JB, Leung A et al. Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus. J VIROLOGY, July 2009, p. 7296\u20137304.","DOI":"10.1128\/JVI.00561-09"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.042_b0115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med."},{"key":"10.1016\/j.vaccine.2020.11.042_b0120","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against marburg virus using a recombinant VSV-vaccine depends on t and B cell activation","volume":"9","author":"Marzi","year":"2019","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.042_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus","volume":"7","author":"Mire","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2020.11.042_b0130","doi-asserted-by":"crossref","unstructured":"Mire CE, Geisbert JB, Agans KN et al. Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates. PLoS ONE 9(4): e94355. doi:10.1371\/journal.pone.0094355.","DOI":"10.1371\/journal.pone.0094355"},{"key":"10.1016\/j.vaccine.2020.11.042_b0135","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/CVI.00431-07","article-title":"Vaccine to confer to nonhuman primates complete protection against multistrain ebola and marburg virus infections","author":"Swenson","year":"2008","journal-title":"Clin Vacc Immunol., Mar."},{"issue":"2","key":"10.1016\/j.vaccine.2020.11.042_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS ONE"},{"issue":"suppl3","key":"10.1016\/j.vaccine.2020.11.042_b0145","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in Rhesus macaques infected with Ebola virus Makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.11.042_b0150","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1128\/CVI.00311-10","article-title":"The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert","volume":"17","author":"Radosevic","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.042_b0155","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiu485","article-title":"Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans","volume":"211","author":"Baden","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.042_b0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-6869-5_6","article-title":"Generation and production of modified Vaccinia Ankara Virus as a Vaccine Vector","volume":"1581","author":"Pavot","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2020.11.042_b0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2020.11.042_b0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/v8040094","article-title":"Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)","volume":"8","author":"Dye","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2020.11.042_b0175","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/v8040094","article-title":"Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses","volume":"8","author":"Swenson","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2020.11.042_b0180","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/jmv.24832","article-title":"Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques","volume":"89","author":"Weiwei","year":"2017","journal-title":"J Med Virol."},{"key":"10.1016\/j.vaccine.2020.11.042_b0185","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector choice determines immunogenicity and potency of vaccines against Angola Marburg virus in nonhuman primates","author":"Geisbert","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.11.042_b0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.11.042_b0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0168-1656(95)00104-2","article-title":"Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys","volume":"44","author":"Ignatyev","year":"1996","journal-title":"J Biotechnology"},{"key":"10.1016\/j.vaccine.2020.11.042_b0200","unstructured":"National Institutes of Health, National Institute of Allergy and Infectious Diseases website. NIAID Emerging Infectious Diseases\/Pathogens. NIAID Biodefense Research. Available at: https:\/\/www.niaid.nih.gov\/research\/emerging-infectious-diseases-pathogens, accessed 19 APR 2019."},{"key":"10.1016\/j.vaccine.2020.11.042_b0205","unstructured":"Centers for Disease Control and Prevention. Select Agent list. Available at: http:\/\/www.selectagents.gov\/SelectAgentsandToxinsList.html, accessed 19 April 2019."},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.042_b0210","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1080\/21645515.2015.1039757","article-title":"Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges","volume":"11","author":"Grant-Klein","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.11.042_b0215","unstructured":"Themis Company Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting, 08 November 2019. Available at: https:\/\/www.fda.gov\/media\/132288\/download, accessed 28 SEP 2020."},{"key":"10.1016\/j.vaccine.2020.11.042_b0220","unstructured":"Valneva. Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate. Available at: https:\/\/valneva.com\/press-release\/valneva-initiates-phase-3-clinical-study-for-its-chikungunya-vaccine-candidate-vla1553\/, accessed 28 SEP 2020."},{"issue":"10","key":"10.1016\/j.vaccine.2020.11.042_b0225","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.11.042_b0230","unstructured":"Sabin Institute. Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines. Available at: https:\/\/www.sabin.org\/updates\/pressreleases\/sabin-vaccine-institute-receives-205-million-barda-potential-128-million, accessed 28 September 2020."},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.042_b0235","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.042_b0240","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Human Vaccines Immunotherapeutics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2031495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2031495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:59Z","timestamp":1759402499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2031495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X2031495X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}